1. Home
  2. MYNZ

as 06-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Founded: 2021 Country:
Germany
Germany
Employees: N/A City: N/A
Market Cap: 12.8M IPO Year: 2021
Target Price: $3.00 AVG Volume (30 days): 160.1K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.62 EPS Growth: N/A
52 Week Low/High: $0.55 - $5.10 Next Earning Date: 06-25-2024
Revenue: $895,479 Revenue Growth: 69.00%
Revenue Growth (this year): 36.69% Revenue Growth (next year): 91.67%

MYNZ Daily Stock ML Predictions

Share on Social Networks: